Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.
Continuing bimekizumab for 2 years led to maintenance of various HiSCR and International Hidradenitis Suppurativa Severity Score System (IHS4) scores.
Orismilast demonstrated higher rates of Investigator Global Assessment of 0/1 at week 16 compared with placebo in the phase 2b ADESOS trial.
A comparison of topical delgocitinib with systemic alitretinoin for treating patients with chronic hand eczema (CHE) favoured the pan-JAK inhibitor.
A comprehensive analysis from the German Psoriasis Registry (PsoBest) highlights the evolution of systemic drug use for psoriasis over the past 15 years.
Delgocitinib was associated with a reduction in interferon gamma (IFN-γ), chemokine ligand (CXCL)9, and CXCL10 in the treatment of FFA.
A study including data from over 30,000 participants revealed that early onset of atopic dermatitis (AD) leads to a psychosocial burden throughout adult life.
Withdrawing nemolizumab led to an 8-fold increase in the likelihood of a prurigo nodularis (PN) relapse compared with uninterrupted therapy.
A combination of eye-tracking tests could help to speed up the diagnostic process and make it more efficient, according to the authors.
A single dose of 750 mg imsidolimab yielded a GPPPGA score of clear or almost clear in over half of the participants with GPP after 4 weeks.
Izokibep treatment for hidradenitis suppurativa (HS) met its primary endpoint of HS Clinical Response (HiSCR)75 in an ongoing phase 3 trial.
A study using full-thickness human skin punches identified critical molecular targets that could transform the treatment of both acute and chronic wounds.
In the randomised study, participants were treated either with magnetic seizure therapy (MST) or with Electroconvulsive Therapy (ECT). What were the results?
Histologic risk status at diagnosis and the time needed to achieve complete remission (CR) may influence the prospect of a relapse after HHI treatment.
In patients with hidradenitis suppurativa and obesity, therapy led to significant weight loss, reduced flares and improved quality-of-life.
A novel anti-KIT antibody demonstrated high rates of well-controlled and fully controlled disease after 1 year of treating chronic spontaneous urticaria.
The EASI90 response in the extension study ADjoin even increased over time with around 80% of patients achieving this high clearance rate at 152 weeks.
Indirect matching-adjusted comparison assessing delgocitinib cream and subcutaneous dupilumab did not detect significant differences in treatment.
Sugary drinks cause weight gain and heart damage. Regarding liver damage, US researchers argue it may depend on the sweeteners.
The study shows how stress triggers relapses. It was presented at the EADV Congress 2024 and scientifically confirms the correlation for the first time in vivo.